and permeability was assessed by electrical cell–substrate impedance sensing.

Measurement and Main Results: In the isolated perfused human lung, CFH increased lung permeability over 2 hours compared with control lungs (12% vs. 2% weight gain from baseline, $P = 0.03$). Increased vascular permeability was confirmed by a 4.8-fold increase in Evans blue dye–labeled albumin in the airspace compared with control lungs. Pretreatment with APAP prevented lung weight gain ($P = 0.06$ vs. CFH). In human pulmonary microvascular endothelial cells, CFH increased monolayer permeability ($P = 0.03$ vs. control), and this was attenuated by APAP ($P = 0.045$ vs. CFH).

Conclusions: Circulating CFH increases vascular permeability in the isolated perfused human lung and paracellular permeability in lung microvascular endothelial cells. These effects may explain the association of plasma CFH levels with PGD. The hemoprotein reductant APAP attenuates the effects of CFH and merits further exploration as a potential therapy for PGD prevention.

Author disclosures are available with the text of this article at www.atsjournals.org.

(Received in original form September 13, 2016; accepted in final form September 21, 2016)

Supported by National Institutes of Health grants HL 103836, HL126176, HL126671, and HL087738, Vanderbilt University Medical Center.

Correspondence and requests for reprints should be addressed to Ciara M. Shaver, M.D., Ph.D., Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, T-1218, Nashville, TN 37232. E-mail: ciara.shaver@vanderbilt.edu

Ann Am Thorac Soc Vol 14, Supplement 3, pp S251–S252, Sep 2017
Copyright © 2017 by the American Thoracic Society
Internet address: www.atsjournals.org

Reference

- 1 Ware LB, Janz DR, Diamond JM, Lederer DJ, Kawut SM, Bhorade S, Palmer SM, Wille KM, Weinacker A, Lama V, et al; Lung Transplant Outcomes Group. Plasma free hemoglobin potentiates the association between reperfusion FiO₂ and primary graft dysfunction after lung transplantation. *J Heart Lung Transplant* 2013;32:S42–S43.

Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction

S. Samuel Weigt¹, Xiaoyan Wang¹, Vyacheslav Palchevskiy¹, Naman Patel¹, Ariss Derhovanessian¹, Michael Y. Shino¹, David M. Sayah¹, Aric L. Gregson¹, Joseph P. Lynch III¹, Rajan Sagar¹, David J. Ross¹, Abbas Ardehali², David Elashoff¹, and John A. Belperio¹

¹Department of Medicine and ²Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California

ORCID IDs: 0000-0001-5351-8936 (S.S.W.); 0000-0001-7021-8273 (D.M.S.); 0000-0003-2379-5486 (J.A.B.).

Chronic lung allograft dysfunction (CLAD) is the main limitation to long-term survival after lung transplantation. Although CLAD is usually not responsive to treatment, earlier identification may improve treatment prospects. In a nested case–control study, 1-year posttransplantation surveillance bronchoalveolar lavage (BAL) fluid samples were obtained from incipient CLAD ($n = 9$) and CLAD-free ($n = 8$) lung transplant recipients. Incipient CLAD cases were diagnosed with CLAD within 2 years, whereas control subjects were free from CLAD for at least 4 years after bronchoscopy. Transcription profiles in the BAL cell pellets were assayed with the HG-U133 Plus 2.0 microarray (Affymetrix, Santa Clara, CA). Differential gene expression analysis, based on an absolute fold change (incipient CLAD vs. no CLAD) greater than 2.0 and an unadjusted P value not exceeding 0.05, generated a candidate list containing 55 differentially expressed probe sets (51 up-regulated, 4 down-regulated). The cell pellets in incipient CLAD cases were skewed toward both innate and adaptive immune responses, suggesting that dysregulated immunity may precede a clinical diagnosis of CLAD. Both hierarchical clustering and a supervised machine learning tool were able to correctly categorize most samples into incipient CLAD and CLAD-free categories. A larger prospective investigation of a BAL cell pellet transcriptome as a biomarker for CLAD risk stratification is warranted.

Author disclosures are available with the text of this article at www.atsjournals.org.

(Received in original form August 18, 2016; accepted in final form August 30, 2016)

Correspondence and requests for reprints should be addressed to S. Samuel Weigt, M.S., M.D., UCLA, Department of Medicine, UCLA Medical Center, Division of Pulmonary and Critical Care Medicine, 37-131 CHS, Box 951690, Los Angeles, CA 90095-1690. E-mail: sweigt@mednet.ucla.edu

Ann Am Thorac Soc Vol 14, Supplement 3, p S252, Sep 2017
Copyright © 2017 by the American Thoracic Society
Internet address: www.atsjournals.org

Bioactive Lipid Mediators Regulate Lung Epithelial and Mesenchymal Cell Reparative Processes *In Vitro*

Tara M. Nordgren¹, Art J. Heires¹, Kristina L. Bailey^{1,2}, and Debra J. Romberger^{1,2}

¹Pulmonary, Critical Care, Sleep, and Allergy Division, University of Nebraska Medical Center, Omaha, Nebraska; and ²Veterans Affairs Nebraska Western Iowa Healthcare System, Omaha, Nebraska

ORCID ID: 0000-0001-6398-8528 (T.M.N.).

Lung wound–healing responses such as the epithelial-to-mesenchymal transition (EMT) can be reparative or pathologic processes. During lung transplantation, wound healing must occur, yet unchecked responses can result in negative outcomes including bronchiolitis obliterans. A class of specialized proresolving lipid mediators (SPMs) derived from omega-3 fatty acids has been found to contribute to the regulation of wound healing, including both positive and negative actions on EMT-related pathways.